SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis
The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site …
Skyrizi for Ulcerative Colitis - HealthCentral
Jul 23, 2024 · Skyrizi (risankizumab) is a prescription medicine for the treatment of moderate to severe ulcerative colitis in adults. It was approved for this indication in June 2024 by the U.S. Food and Drug ...
Risankizumab for Ulcerative Colitis: Two Randomized Clinical ...
Sep 17, 2024 · Abstract Importance: The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown. …
Risankizumab-rzaa | Crohn's & Colitis Foundation
Patients should be evaluated for tuberculosis (TB) prior to starting this medication, and should not be given Skyrizi® if there is active TB. If there is a hypersensitivity reaction or anaphylaxis occurs, …
Risankizumab-rzaa (SKYRIZI) in Ulcerative Colitis National Drug Monograph February 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The purpose of VA …